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Abstract
One of the hallmarks of B lymphoid malignancies is a B cell clone characterized by a unique footprint of clonal
immunoglobulin (IG) gene rearrangements that serves as a diagnostic marker for clonality assessment. The
EuroClonality/BIOMED-2 assay is currently the gold standard for analyzing IG heavy chain (IGH) and κ light chain
(IGK) gene rearrangements of suspected B cell lymphomas. Here, the EuroClonality-NGS Working Group presents a
multicentre technical feasibility study of a novel approach involving next-generation sequencing (NGS) of IGH and IGK
loci rearrangements that is highly suitable for detecting IG gene rearrangements in frozen and formalin-ﬁxed parafﬁn-
embedded tissue specimens. By employing gene-speciﬁc primers for IGH and IGK amplifying smaller amplicon sizes in
combination with deep sequencing technology, this NGS-based IG clonality analysis showed robust performance, even
in DNA samples of suboptimal DNA integrity, and a high clinical sensitivity for the detection of clonal rearrangements.
Bioinformatics analyses of the high-throughput sequencing data with ARResT/Interrogate, a platform developed within
the EuroClonality-NGS Working Group, allowed accurate identiﬁcation of clonotypes in both polyclonal cell
populations and monoclonal lymphoproliferative disorders. This multicentre feasibility study is an important step
towards implementation of NGS-based clonality assessment in clinical practice, which will eventually improve
lymphoma diagnostics.
Introduction
The vast majority of lymphoid malignancies arise from the
unconstrained expansion of a single transformed B or T cell
and is characterized by the presence of clonal rearrange-
ments of immunoglobulin (IG) or T cell receptor (TR) genes
[1, 2]. In the case of B cell lymphoma, the germline variable
(V), diversity (D), and joining (J) genes of the IG loci
become rearranged during early development and undergo
random deletion and insertion of nucleotides within the
junctional regions, thereby generating speciﬁc and unique
sequences for each B lymphocyte [3]. Additional diversi-
ﬁcation of the IG repertoire is achieved by the introduction
of somatic mutations into the V domain [4]. These “DNA
ﬁngerprints” can serve as clonality markers to study lym-
phoproliferative disorders. Indeed, clonality assessment
represents an objective supplementary diagnostic approach
to distinguish lymphoid malignancies from non-neoplastic
processes [5, 6]. Furthermore, evaluation of the clonal
relationship between a primary and recurrent lymphoma via
clonality analysis provides an essential tool to conﬁrm the
occurrence of a relapse.
At present, the EuroClonality/BIOMED-2 multiplex
PCR-based protocol for IG/TR targets combined with
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heteroduplex analysis or fragment length (GeneScan) ana-
lysis, represents the gold standard for clonality assessment
of lymphoid tissues [7–9]. Many diagnostic laboratories
have extensively validated this protocol for clonality ana-
lyses of lymphoma specimens [10–13]. The EuroClonality/
BIOMED-2 approach has been designed for optimal DNA
samples with amplicons in the range of 150–400 bp.
However, in formalin-ﬁxed parafﬁn-embedded (FFPE)
samples with low-quality DNA, clonal rearrangements
corresponding to long amplicons may potentially be missed,
leading to false-negative results. Moreover, interpretation of
clonality patterns in suboptimal DNA samples is not always
straightforward, making it difﬁcult to establish whether
rearrangement proﬁles are truly clonal, oligoclonal, or
polyclonal. Furthermore, establishing the clonal relationship
between a primary lymphoma and its recurrence currently
relies mainly on the demonstration of identically sized
amplicons; that said, differently sized fragments can still
represent the same rearrangement, however they may also
describe different clonal lymphoid populations. Conﬁrma-
tion by actual sequence information of the clone is war-
ranted, but Sanger sequencing of less pronounced clones is
labor intensive and not always feasible.
In the past decade, high-throughput sequencing of
DNA and RNA molecules has been successfully intro-
duced into the ﬁeld of immunology and hematology,
including in-depth analyses of the immune repertoire by
next-generation sequencing (NGS)-based detection of IG
and TR rearrangements in both physiological and patho-
logical contexts [14–19]. Other applications in hemato-
oncology involving V(D)J-NGS include clonal evolution
of lymphoid malignancies [20, 21], biomarker tracing
employing liquid biopsies [22, 23], and monitoring of
minimal residual disease (MRD) [24–27]. The large
majority of these studies have been focused on obtaining
full sequence coverage of complete IG heavy chain
IGHV-IGHD-IGHJ gene rearrangements. In addition,
several bioinformatics tools have been developed for V
(D)J germline assignment and detection of IGH and IG κ
light chain (IGK) rearrangements within reads obtained
from NGS datasets [28–32].
In recent years, the EuroClonality-NGS Working Group
has developed IG/TR assays, which have been validated
across expert European centres to allow for quality-con-
trolled, streamlined, and comprehensive detection of clonal
IG/TR rearrangements [33, 34]. Here, we describe the
modiﬁcation and application of the EuroClonality-NGS
IGH and IGK assays for B cell clonality detection focusing
on small amplicon sizes, highly suitable for analysis of
FFPE samples. NGS-based clonality assessment was com-
pared to the conventional EuroClonality/BIOMED-2
approach to evaluate its performance for the detection of IG
gene rearrangements.
Materials and methods
Tissue specimens
Human peripheral blood and tonsillar tissue were obtained
from healthy individuals at Erasmus MC, Rotterdam and
Radboudumc, Nijmegen. A total of 14 FFPE tissue speci-
mens from 10 patients with B cell lymphoma were ran-
domly selected for this study (Supplementary Table S1),
and analyzed both by conventional EuroClonality/
BIOMED-2 assay and NGS. All samples were retrieved
from the local archive of the Department of Pathology at
Radboudumc and Charité-Universitätsmedizin Berlin and
collected in accordance with the declaration of Helsinki.
Sample preparation for clonality detection by next
generation sequencing
Multiplex PCR was adapted from the EuroClonality-NGS
IG/TR assays [34], and optimized for B cell clonality
detection, including IGHV-IGHD-IGHJ, IGHD-IGHJ, and
IGK (IGKV-IGKJ, IGKV-KDE, and Intron RSS-KDE)
rearrangements (Supplementary Fig. S1; Supplementary
Table S2). EuroClonality-NGS IG primers allow detection
of all IGH and IGK genes classiﬁed as functional or open-
reading frame (ORF) (Supplementary Table S3). Each 25 μl
PCR reaction contained 40 ng DNA (or lower amounts in
case of sensitivity testing), 2.5 μl GeneAmp 10x PCR Gold
Buffer (Thermo Fisher Scientiﬁc, Waltham, MA, USA), 0.2
or 0.4 μM of the forward and reverse primers, 200 μM
dNTPs, 0.5 U AmpliTaq Gold DNA polymerase (Thermo
Fisher Scientiﬁc, Waltham, MA, USA), and either 1.5 mM
MgCl2 (IGHV-VJ-FR3 and IGK primer sets) or 2.0 mM
MgCl2 (IGH-DJ primer set). After the PCR reactions were
completed, the contents of the tubes were pooled and
amplicons were puriﬁed by the Agencourt AMPure XP kit
(Beckman Coulter, Brae, CA, USA).
Details regarding materials and methods, including ion
torrent sequencing and bioinformatics analysis are provided
as Supplementary Information.
Results
IGH and IGK primers for NGS-based clonality
assessment
For the identiﬁcation of IGHV-IGHD-IGHJ gene rearran-
gements by NGS, speciﬁc forward primers were designed
for variable heavy framework 3 (VH FR3) (Fig. 1a), which
allows detection of smaller amplicon sizes compared to
IGH-VJ-FR1 and IGH-VJ-FR2 forward primers. NGS of
IGHV-IGHD-IGHJ gene rearrangements in a control tonsil
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sample followed by bioinformatics analysis with ARResT/
Interrogate [32] resulted in the detection of multiple clo-
notypes, representing a distribution of different amino acid
(aa) junction lengths, which reﬂected a polyclonal B cell
population (Fig. 1b), similar to GeneScan proﬁles using
EuroClonality/BIOMED-2 primers (Fig. 1c). For the iden-
tiﬁcation of partial IGHD-IGHJ gene rearrangements, we
employed the same IGH-DJ primer sets as described for
MRD marker identiﬁcation [34]. For the detection of IGK
locus gene rearrangements, we also used the same primers
as for MRD marker identiﬁcation, but multiplex PCR was
performed within a single tube and PCR conditions were
adapted to allow simultaneous ampliﬁcation of IGKV-IGKJ
and IGKV/Intron-KDE gene rearrangements. NGS of IGK
locus gene rearrangements in a control tonsil sample yielded
a distinctive polyclonal pattern of clonotypes of different aa
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junction length similar to what could be detected by the
EuroClonality/BIOMED-2 proﬁles for IGKV-IGKJ and
IGKV/Intron-KDE gene rearrangements (Supplementary
Fig. S2).
Validation of NGS primers for IGH and IGK clonality
analysis
To validate the IGH and IGK primers using the NGS-based
clonality protocol, we performed NGS on different control
samples in a multicentre study involving four different
centres, namely Radboudumc in Nijmegen (NIJ; Lab A),
Erasmus MC in Rotterdam (ROT; Lab B), Charité in Berlin
(BER; Lab C), and the Comprehensive Cancer Center in
Tübingen (TUB, Lab D). The DNA control samples con-
sisted of two peripheral blood mononuclear cells (PBMC)
samples, which are known to harbor 5–15% B cells, and
two tonsil tissue specimens derived from healthy donors
with ~50–60% B cells. By employing data analysis in
ARResT/Interrogate, we examined if all functional and
ORF genes for the IGHV, IGHD, and IGKV regions were
covered (Fig. 2, Supplementary Table S4). For IGHV, all
functional IGHV genes (n= 55) and 6 of the 7 ORFs
located on chromosome 14q32 were detected by the IGH-
VJ-FR3 primer set (Supplementary Table S4). Similar to
what has been described for MRD marker identiﬁcation
[34], all 22 functional genes and all 4 ORF of the IGHD
region could be identiﬁed (Fig. 2). For the IGKV region, all
functional genes (n= 41), and 6 of the 7 ORFs located on
chromosome 2p11 were detected by the IGK-VJ primer set.
Thus, virtually all functional IG genes and ORFs were
detected by the EuroClonality-NGS primers using the IG
clonality protocol.
Robust detection of IG gene rearrangements in FFPE
material by NGS
To assess whether our NGS-based protocol for detection of
IG gene rearrangements performed equally well on DNA
extracted from frozen and FFPE tissues, we determined the
spectrum of IGH and IGK gene rearrangements in both
material types, using paired samples of the same biopsy of
two independent tonsil specimens. DNA was extracted in
one reference laboratory and NGS on ampliﬁed IGH and
IGK gene rearrangements was performed using Ion Torrent
technology in the four different centres (NIJ, ROT, BER,
and TUB).
Analysis of the DNA quality showed that the frozen-
tissue DNA samples (Tonsil1 and Tonsil3) displayed high
DNA quality, while the FFPE samples (Tonsil2 and Ton-
sil4) displayed shorter fragment length (Supplementary
Fig. S3). Bioinformatics analysis by ARResT/Interrogate
indicated that, despite the different DNA quality, the var-
iation in total reads obtained for IGH and IGK loci gene
rearrangements was largely comparable between frozen and
FFPE tissue at each center, ranging from 56,722 to 204,038
reads for frozen-tissue samples, and 40,476 to 224,374
reads for FFPE samples (Supplementary Table S5). The
percentage of mapped reads (i.e. reads with an identiﬁable
junction) varied between different centres, ranging from
62% to 88%. The average fraction of mapped reads that
could be assigned to IGHV-IGHD-IGHJ gene rearrange-
ments was 37% in frozen-tissue and 28% in FFPE, for
IGHD-IGHJ 17% in frozen-tissue and 19% in FFPE, and
for IGK locus 46% in frozen-tissue and 54% in FFPE
(Supplementary Table S5).
The IGHV, IGHD, and IGKV genes (functional and
ORFs) that were identiﬁed in the clonotypes of the two tonsil
specimens displayed a similar distribution in frozen and FFPE
tissue samples in each of the four centres (Fig. 3; Supple-
mentary Table S6). Individual IGHV and IGHD genes were
present at higher frequencies in both frozen and FFPE tonsil
specimens. The most prevalent IGHV genes included
IGHV3-9, IGHV3-23, IGHV3-30, IGHV3-74, and IGHV4-
34, while IGHD3-3, IGHD3-9, IGHD3-10, and IGHD3-22
represented the predominant IGHD genes (Fig. 3; Supple-
mentary Table S6). The different IGKV genes were more
equally distributed among the rearrangements detected in both
frozen and FFPE tissues. Furthermore, we observed that the
pattern of IGHJ gene usage for IGHV-IGHJ gene rearrange-
ments was different compared to that for IGHD-IGHJ gene
rearrangements (Fig. 3). In both frozen and FFPE tissue, the
IGHJ4 gene predominated amongst the IGHV-IGHD-IGHJ
rearrangements, while IGHJ6 was more abundant among the
Fig. 1 Identiﬁcation of distinct clonotypes by next generation
sequencing (NGS)-based detection of immunoglobulin heavy chain
rearrangements. a Schematic representation of the immunoglobulin
heavy chain (IGH) locus on chromosome 14q32, indicating the pre-
sence of 62 IGHV genes, 27 IGHD genes, 6 IGHJ genes, and 5 IGHC
genes. Following RAG-mediated DJ and V-DJ rearrangement, each B
cell generates one (productive rearrangement) or two (a non-
productive and productive rearrangement) speciﬁc clonotypes, each
consisting of one IGHV, IGHD, and IGHJ gene segment. For the
detection of IGHV-IGHD-IGHJ gene rearrangements the forward
IGHV primers located in framework region 3 (VH FR3) are combined
with IGHJ reverse primers. For the detection of IGHD-IGHJ rearran-
gements the forward IGHD and reverse IGHJ primers will generate
amplicons. Successful ampliﬁcation will yield DNA fragments that
cover the junctional region with a speciﬁc amino acid (aa) length,
representing the CDR3 region and anchor points. The leader region
(L), the conserved framework regions 1–4 (FR1–4) and the hyper-
variable complementary regions 1–3 (CDR1–3) are indicated.
b Detection of distinct clonotypes in DNA isolated from a frozen tonsil
tissue of a healthy donor (Tonsil3), indicating a polyclonal pattern of
IGHV-IGHD-IGHJ rearrangements with variable junction aa length.
Each colored bar indicates a distinct clonotype, and the 100 most
abundant clonotypes are shown. The NGS data were analyzed and
visualized by ARResT/Interrogate. c GeneScan proﬁle of Tonsil3
IGHV-IGHD-IGHJ rearrangements as determined with EuroClonality/
BIOMED-2 PCR
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IGHD-IGHJ rearrangements. The distribution of IGKJ genes
in IGKV-IGKJ gene rearrangements was more balanced, with
a slight predominance for the IGKJ4 gene. Collectively, these
data demonstrate that there is a high reproducibility in the
identiﬁcation of clonotypes in polyclonal tonsil specimens
between frozen and FFPE tissues, and also among different
centres.
Performance parameters of NGS-based clonality
analysis
Next, the minimal DNA amount that would be required for
reliable performance of clonality assessment was deter-
mined. This is crucial information for the interpretation of
clonality in case of tumor specimens with scarce presence of
lymphoid cells or small biopsies. A known pitfall in these
situations is the risk of pseudoclonality, which may arise
from selective ampliﬁcation of only a few target cells [35].
By analyzing the pattern of IGH and IGK locus gene
rearrangements with decreasing concentrations of input
DNA isolated from polyclonal tonsil tissue of FFPE origin,
the transition from a regular polyclonal rearrangement pat-
tern to pseudoclonality or absence of IG gene rearrangement
was determined. Analysis of IGHV-IGHD-IGHJ gene
rearrangements demonstrated that 40, 20, and 10 ng of input
DNA for each multiplex PCR reaction produced a similar
distribution and abundance of IGHV and IGHJ genes
(Fig. 4a). At 5 ng DNA, the polyclonal proﬁle started to
change to a less diverse rearrangement pattern, while at 2.5
ng DNA there was clear evidence of pseudoclonality or
immunodominance of several IGHV genes, with many
other IGHV genes not being detected (Fig. 4a). These
analyses indicate that an input range of 10–40 ng of Qubit
quantiﬁed DNA per multiplex PCR can be used for IG
clonality analysis. Nevertheless, a larger series of small
tissue biopsies with variable amounts of suspect malignant
lymphocytes and reactive lesions need to be analyzed to
assess the exact minimum amount for reliable clonality
assessment in biopsy material.
In a similar approach, we also investigated the limit of
detection using two clonal B cell lymphoma specimens
(Diag1: 80% tumor cells; Blym6: 10% tumor cells), by
testing a range of 1.25–40 ng of input DNA for each mul-
tiplex PCR reaction. Here, clonal rearrangements could still
be detected at the lowest input concentration of 1.25 ng
(Fig. 4b), indicating that NGS can detect rearrangements at
this low DNA concentration in case of a clonal B cell
lymphoma. Next, we analyzed four B cell lymphoma
IMGT IGHV IGHD IGKV
Functional genes 55/55 (100%) 22/22 (100%) 41/41 (100%)
ORFs 6/7 (86%) 4/4 (100%) 6/7    (86%)
Fig. 2 Schematic representation of the procedure to validate the pri-
mers designed for immunoglobulin clonality assessment by next-
generation sequencing. The lower graph shows a representative plot of
the data indicating the relative percentage of the different IGKV genes
(5’ gene) in combination with speciﬁc IGKJ genes in peripheral blood
mononuclear cells (PBMC2). Each set of four bars demonstrate the
data as obtained for each of the four centres (Lab A, Lab B, Lab C, and
Lab D) participating in the multicentre feasibility study
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specimens (Blym1, Blym3, Blym5, and Diag1) with a high
tumor load (80–90%) in a dilution series at concentrations
of 10%, 5%, 2.5%, and 1% in a polyclonal background of
FFPE tonsil DNA, using a ﬁxed amount of total input DNA
(40 ng). The data for IGHV-IGHD-IGHJ, IGHD-IGHJ, and
IGKV-IGKJ gene rearrangements demonstrated that, in the
majority of cases, clonal rearrangements could be traced
back at 10%, 5%, and 2.5% dilutions (Supplementary
Fig. S4). For two of the four B cell lymphoma dilution
series, the abundant clonotype for IGHD-IGHJ and IGKV-
IGKJ gene rearrangements could even be detected at a level
of 1% within the polyclonal background signal (Supple-
mentary Fig. S4).
Comparison between EuroClonality/BIOMED-2 and
NGS for clonality assessment
Prior to implementation of NGS-based analysis of IG gene
rearrangements for clonality detection of lymphoid
malignancies, we wanted to critically compare this novel
technique to the gold standard EuroClonality/BIOMED-2
assay. To this end, a total of 14 distinct B cell lymphoma
samples that were previously tested with EuroClonality/
BIOMED-2 PCR and GeneScan analysis in routine diag-
nostics, were included in our NGS multicentre study
(Supplementary Table S1; Supplementary Fig. S5). The
IGHV-IGHD-IGHJ, IGHD-IGHJ, IGKV-IGKJ, and IGKV/
Intron-KDE clonotypes were determined by NGS in two
different centres and analyzed by ARResT/Interrogate. The
graphical output of the clonotypes as obtained by NGS was
compared with the EuroClonality/BIOMED-2 GeneScan
data. In the majority of cases (38 out of 50 targets with a
clonal rearrangement), the number of dominant IG gene
rearrangements that could be identiﬁed by NGS was iden-
tical to those identiﬁed using the EuroClonality/BIOMED-2
approach (Table 1; Supplementary Table S7). For instance,
in B cell lymphoma specimen Blym1, abundant clonotypes
for IGHV-IGHD-IGHJ (IGHV3-23(D)/IGHJ4), IGHD-
Fig. 3 Identiﬁcation of similar B cell clones in both formalin-ﬁxed and
frozen tonsil tissue. IGH (IGHV-IGHD-IGHJ and IGHD-IGHJ) and
IGK loci gene rearrangements were sequenced in two DNA samples
isolated from either frozen tissue (left bar, Tonsil3) or formalin-ﬁxed
parafﬁn-embedded (FFPE) (right bar, Tonsil4) material derived from
the same tonsil specimen. The IGHV, IGHD, and IGKV genes
detected are indicated on the X-axis (5’ gene) in combination with the
different IGHJ (ﬁrst and second graphs) and IGKJ/KDE genes (third
graph) as indicated by the stacked colored bars. Data shown are
representative for each of the four centres participating in the multi-
centre feasibility study
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IGHJ (IGHD2-2/IGHJ6), IGKV-IGKJ (IGKV1(D)-39/
IGKJ4), IGKV-KDE (IGKV2(D)-30/KDE), and Intron-
KDE were detected, although in this sample the results
for IGHD-IGHJ gene rearrangement detection slightly var-
ied between the two centres (Fig. 5).
Importantly, for 11 out of 50 targets (22%), NGS-based
clonality assessment identiﬁed clonal rearrangements that
were not detected by EuroClonality/BIOMED-2, an
improvement primarily due to the alternative primer design
towards shorter amplicons (Table 1). For instance, in
Blym2, the EuroClonality/BIOMED-2 primers identiﬁed
only one abundant IGKV-IGKJ gene rearrangement, while
NGS detected the presence of bi-allelic IGKV-IGKJ gene
rearrangements with the concomitant identiﬁcation of two
clonotypes (IGKV4-1/IGKJ4 and IGKV3(D)-7/IGKJ5)
(Fig. 6). The IGKV4-1/IGKJ4 clonal rearrangement is
expected to yield a product in the 275–295 bp range using
the EuroClonality/BIOMED-2 approach, which could not
be ampliﬁed in this apparently suboptimal DNA sample. In
Blym4, NGS again detected bi-allelic IGKV-IGKJ gene
rearrangements, of which only one was detected by the
EuroClonality/BIOMED-2 assay (Supplementary Fig. S6).
There was only one instance in which the NGS-based
approach failed to detect a rearrangement that was identiﬁed
with EuroClonality/BIOMED-2 primers (Table 1; Supple-
mentary Table S8); in Blym3, the dominant IGHV-IGHD-
IGHJ gene rearrangement detected by GeneScan, was only
present as a minor clonotype using NGS, which could be
attributed to two mismatches between the DNA sequence
and the NGS IGHV primer. Collectively, these results
demonstrate that NGS-based detection of IG gene rearran-
gements is a feasible approach for clonality assessment of
FFPE specimens of lymphoproliferative disorders, and even
shows improved performance compared with the current
EuroClonality/BIOMED-2 approach.
Analysis of diagnosis-relapse cases by NGS-based
detection of IG gene rearrangements
At present, the clonal relationship between B cell lym-
phoma recurrences at subsequent timepoints or from mul-
tiple lesions at different locations is mostly established by
fragment length analysis of IG gene rearrangements using
the EuroClonality/BIOMED-2 assay. However, in some
situations these assays remain inconclusive, because the
limited amounts of biopsy material or archival tissue
material yielding suboptimal DNA quality, does not allow
perfect reproducibility of the obtained GeneScan or
Fig. 4 Sensitivity of next-generation sequencing (NGS)-based clon-
ality assessment on lymphoid tissue and lymphoma specimens. a The
abundance of IG gene rearrangements and the relative distribution of
clonotypes was analyzed using decreasing concentrations of Qubit-
quantiﬁed input DNA for each multiplex PCR reaction, ranging from
40 to 2.5 ng, of a formalin-ﬁxed parafﬁn-embedded (FFPE) tonsil
specimen (Tonsil2). At 2.5 ng input DNA several IGHV-IGHD-IGHJ
sequences showed evidence of pseudoclonality (indicated by circles)
or were not detected at all (indicated by arrows). b Two clonal B cell
lymphoma specimens (Diag1 and Blym6) were tested in NGS-based
clonality analysis using decreasing amount of input DNA (40–1.25
ng). The data as obtained for IGKV-IGKJ gene rearrangement analysis
is presented, with detection of the abundant clone even at 1.25 ng input
DNA. The green (IGKV5-2/IGKJ2) and orange (IGKV1D-8/IGKJ4)
bar of Diag1 represent bi-allelic IGKV-IGKJ gene rearrangements.
The green (IGKV1(D)-39/IGKJ2= J3) and orange (IGKV1(D)-39/
IGKJ2) bars of Blym6 represent the same clonotype but ARRest/
Interrogate distinguished two variants, since the sequence of the IGKJ
gene was assigned differently. The purple, pink, and other colored bars
represent additional minor clonotypes
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heteroduplex patterns. NGS-based clonality assessment has
the advantage of generating sequence information of the
detected clonotypes, thereby providing deﬁnite evidence
whether tumors are clonally related or not. In our multi-
centre validation study we included four paired diagnosis-
relapse samples (Supplementary Table S1) to assess the
added value of the NGS-based approach for this application.
In the Diag1 and Relap1 samples, a single IGHV-IGHD-
IGHJ and IGHD-IGHJ gene rearrangement could be
detected, which showed identical clonotypes and sequence
information for the paired diagnosis and relapse samples
(Fig. 7). For IGK, two clonotypes could be identiﬁed for
IGKV-IGKJ and IGKV/Intron-KDE, respectively, in both
diagnosis and relapse samples, which harbored identical
sequences in both lymphoma specimens, thereby estab-
lishing their clonal relationship.
On the other hand, the distinct clonotypes that were
identiﬁed for IGH and IGK gene rearrangements in the
paired Diag2 and Relap2 samples conﬁrmed the data from
the GeneScan analysis that these were clonally unrelated B
cell tumors (Supplementary Table S1 and S7). In samples
Diag3 and Relap3, a clonal IGKV-KDE rearrangement of
the same clonotype could be identiﬁed in each of the
samples, thus providing evidence that these two samples
were most likely clonally related. Finally, the paired sam-
ples Diag4 and Relap4 displayed distinct IGHV-IGHD-
IGHJ and IGHD-IGHJ gene rearrangements at diagnosis
and relapse, while speciﬁc IGK locus rearrangements were
only detected at diagnosis (Supplementary Table S7), sug-
gesting that these lymphoma samples were most likely
clonally distinct. In conclusion, the NGS-based approach
for clonality assessment provides the desired diagnostic
accuracy in conﬁrming the clonal relationship of the
ampliﬁed rearrangements in multiple lesions over time.
Discussion
Clonality testing for IGH and IGK locus gene rearrange-
ments is an important diagnostic test to distinguish reactive
lesions from malignant lymphoproliferative disorders and to
establish the clonal relationship of recurrent lesions within
the same patient. With the advent of high-throughput NGS
of B cell receptor V(D)J gene rearrangements and the
development of bioinformatics platforms for processing
analysis and visualization, a more sensitive approach for
clonality assessment is within reach. As the EuroClonality-
NGS Working Group, we here present a multicentre feasi-
bility study employing deep sequencing of rearranged IGH
and IGK genes to analyze the clonal composition of B cell
lymphoma samples, also suitable for DNA isolated from
FFPE specimens. Tumor-speciﬁc IGK locus gene rearran-
gements and their speciﬁc clonotypes could be detected in
all 14 samples (100%) analyzed by NGS, while IGHV-
Table 1 Summary
immunoglobulin clonality
assessment by GeneScan-
EuroClonality/BIOMED-2 assay
and next-generation
sequencing (NGS)
IGHV-IGHD-IGHJ
GeneScan NGS
IGHD-IGHJ
GeneScan NGS
IGKV-IGKJ
GeneScan NGS
IGKV/Intron-KDE
GeneScan NGS
Blym1 1R 1R 1R 1R 1R 1R 2R 2R
Blym2 1R+PCB 1Ra 1R 1R 1R+PCB 2R 2R+PCB 2R
Blym3 1R Ob 1R 1R 1R+PCB 2R 2R 2R
Blym4 1R 1R 1R+PCB 1R 1R+PCB 2R 1R 1R
Blym5 O 1R 1R 1R 1R 1R 2R 2R
Blym6 1R 1R Nsp 1Ra 1R+PCB 1R 1R 1R
Diag1 1R 1R 1R 1R 1R 2R 2R 2R
Relap1 1R 1R 1R 1R 1R 2R 2R 2R
Diag2 Nsp O 1R 1R 2R 2R 2R 2R
Relap2 1R 1R 1R 1R 1R 1R 1R+PCB 2R
Diag3 P P P P P P 1R 1R
Relap3 P P 1R+PCB 1R+PCB P 1R+PCB 1R+PCB 1R
Diag4 P 1R 1R 1R Nsp P Nsp 2R
Relap4 1R+PCB 1R+PCB 1R+PCB 1R 1R+PCB 1R+PCB 1R+PCB 1R+PCB
Colors used: blue, inferior performance NGS compared to GeneScan with EuroClonality/BIOMED-2
primers; green, improved performance NGS compared to GeneScan with EuroClonality/BIOMED-2 primers
1R one clonal gene rearrangement, 2R two clonal gene rearrangements, PCB polyclonal background, O
oligoclonal: multiple clones, Nsp no speciﬁc product, P polyclonal
aRelated clonotypes belonging most likely to one gene rearrangement, single nucleotide variations probably
due to somatic hypermutation or sequencing artifacts
bMismatches on template of NGS IGHV primer probably due to somatic hypermutation
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IGHD-IGHJ and IGHD-IGHJ gene rearrangements were
detected in 10 of 14 (71%), and 13 of 14 (93%) B cell
lymphoma cases by NGS, respectively. Overall, a speciﬁc
clonotype could be detected by NGS in all 14 samples
analyzed. Even though this is a high fraction, larger vali-
dation studies are required to more ﬁrmly establish the high
clinical sensitivity of our novel EuroClonality-NGS B cell
clonality approach.
We established that for clonality assessment an input
range of 10-40 ng of Qubit-quantiﬁed DNA is required for
each multiplex PCR reaction, while in a lymphoma speci-
men with a high percentage of suspect malignant lymphoid
Fig. 5 Next-generation sequencing (NGS)-based clonality assessment
detects clonal rearrangements in B cell lymphoma specimen. B cell
lymphoma specimen Blym1 was analyzed for IGH (IGHV-IGHD-
IGHJ and IGHD-IGHJ) and IGK (IGKV-IGKJ and IGKV/Intron-
KDE) loci gene rearrangements by NGS (a–d) in two independent
centres (Lab A and Lab B) and compared to EuroClonality/BIOMED-
2 assay (e, f). The sequence of the abundant clonotypes is shown, with
the nucleotide junction sequence in capitals [33], and ﬂanking
sequences in lower case, which have been trimmed to 20
nucleotides length
Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical. . .
Fig. 6 Detection of immunoglobulin gene rearrangements in lym-
phoma specimen with low tumor load by next-generation sequencing
(NGS)-based clonality assessment. B cell lymphoma specimen Blym2
(20% malignant B cells) was analyzed for IGH (IGHV-IGHD-IGHJ,
IGHD-IGHJ) and IGK (IGKV-IGKVJ and IGKV/Intron-KDE) loci
gene rearrangements by NGS (a–d) in two independent laboratories
(Lab A and Lab B) and compared to EuroClonality/BIOMED-2 assay
(e, f). The sequence of the abundant clonotypes is shown, with the
nucleotide junction sequence in capitals [33], and ﬂanking sequences
in lower case, which have been trimmed to 20 nucleotides length. PCB
polyclonal background
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Fig. 7 Comparison paired diagnosis-relapse B cell lymphoma speci-
men by next-generation sequencing (NGS)-based clonality analysis.
Two consecutive B cell lymphoma specimens (Diag1 and Relap1)
from the same patient were analyzed for IGH (IGHV-IGHD-IGHJ and
IGHD-IGHJ) and IGK (IGKV-IGKJ and IGKV/Intron-KDE) loci gene
rearrangements by NGS (a–d) and compared to EuroClonality/
BIOMED-2 assay (e, f). The sequence of the abundant clonotypes are
shown, with the nucleotide junction sequence in capitals [33], and
ﬂanking sequences in lower case, which have been trimmed to 20
nucleotides length
Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical. . .
cells, even 5 ng DNA might allow detection of a clonotype.
However, the absolute minimum amount of DNA for reli-
able clonality analysis, especially from small biopsies with a
much more restricted B cell repertoire, still needs to be
assessed in future studies using a larger series of such
biopsies.
Similar to the BIOMED-2 approach, NGS-based clon-
ality assessment also relies on an initial multiplex PCR step,
which could still be hampered by somatic hypermutation
and speciﬁc polymorphisms that might prevent primer
annealing. Nonetheless, we observed that our newly
designed primers, which are aimed to generate shorter
amplicons suitable for NGS-based clonality assessment on
both Ion Torrent and Illumina platforms, allowed identiﬁ-
cation of additional rearrangements that could not be
detected by the conventional EuroClonality/BIOMED-2
assay. From the 14 lymphoma specimens that were ana-
lyzed, NGS could additionally detect 12 clonotypes (two
IGHV-IGHD-IGHJ, one IGHD-IGHJ, six IGKV-IGKJ and
three IGKV/Intron-KDE) compared to the EuroClonality/
BIOMED-2 approach. Conversely, the NGS approach
failed to detect one abundant clonotype that was detected
with the EuroClonality/BIOMED-2 approach, probably due
to mismatches within the NGS forward primer. Further-
more, when we analyzed the paired diagnosis–relapse
samples we observed that the available sequence informa-
tion of the speciﬁc clonotypes provided supportive and
detailed information for establishing clonal relationship of
the B cell lymphoma recurrences.
We demonstrated that all functional IGHV, IGHD, and
IGKV genes, as well as the majority of the ORF genes were
detectable by the EuroClonality-NGS approach. However,
we observed that the relative representation of the indivi-
dual IG genes varied to some extent between the different
centres. This variation seemed to partially correlate with
distinct efﬁciencies of the individual multiplex PCR and the
assignment of mapped reads due to differences in local
facilities and Ion Torrent sequencers (Supplementary
Table S5). Thus, internal controls employing deﬁned and
standardized polyclonal samples, or established spike-in
standards as described elsewhere [33], will be important
quality controls for NGS-based approach of IG clonality
assessment in a diagnostic setting.
In the current study, we observed distinct usage of the
different V and J genes in the B lymphocyte populations of
peripheral blood and tonsil control samples of healthy
individuals. The IGHV3 subgroup genes were the most
frequent, with a strong predominance of IGHV3-7, IGHV3-
21, IGHV3-23, IGHV3-30, and IGHV3-48 genes (Supple-
mentary Table S4), similar to what others have described in
repertoire analyses in normal controls [14, 15]. Further-
more, the IGHJ4 gene predominated in IGHV-IGHD-IGHJ
gene rearrangements, in keeping with observations in naïve,
transitional, and memory B cells [15]. For IGHD genes,
there was bias to the usage of the IGHD3-3, IGHD3-9,
IGHD3-10, and IGHD3-22 genes, as also detected by others
[14]. Overall, these ﬁndings demonstrate that our newly
designed and validated NGS primers can be applied for
several high-throughput immunogenetic applications, more
particularly clonality assessment, as indicated in this report,
and MRD marker identiﬁcation [34]. A comparison in
turnaround time and costs between conventional Euro-
Clonality/BIOMED-2 and NGS is described in Supple-
mentary Fig. S7 and Supplementary Table S9. By extending
these studies to various patient categories and immunolo-
gical entities with a predisposition to lymphoid malig-
nancies, such as Sjögren syndrome, and
lymphoproliferative disorders associated with viral and
bacterial infections, speciﬁc guidelines should eventually be
deﬁned to distinguish reactive lesions from malignant
lymphoma.
Indeed, an important aspect that has to be re-evaluated in
the context of NGS-based clonality assessment is the term
clonality and its clinical usage. In particular, in lymphoma
specimens with low numbers of (suspect) malignant lym-
phoid cells, few reads from malignant B cell clones might
be indistinguishable from reactive B cell clonotypes, espe-
cially in those cases without knowledge of an already
identiﬁed B cell clone. Therefore, it should be ﬁrmly
established which repertoire is to be expected in healthy
individuals, and in patients with reactive clonal expansions
due to infections, or those with immunological disorders.
Moreover, future studies need to deﬁne the spectrum of
mono-, oligo-, and polyclonality in patient samples, and
also recognize certain patterns of repertoire skewing that
may indicate reactive lesions, thereby deﬁning clinically
relevant thresholds for clonality assessment.
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